Remsing Lily L, Garcia-Bernardo Jose, Gonzalez Ana, Künzel Eva, Rix Uwe, Braña Alfredo F, Bearden Daniel W, Méndez Carmen, Salas Jose A, Rohr Jürgen
Department of Pharmaceutical Sciences, College of Pharmacy, Medical University of South Carolina, 280 Calhoun Street, P.O. Box 250140, Charleston, South Carolina 29425, USA.
J Am Chem Soc. 2002 Feb 27;124(8):1606-14. doi: 10.1021/ja0105156.
Mithramycin is an aureolic acid-type antimicrobial and antitumor agent produced by Streptomyces argillaceus. Modifying post-polyketide synthase (PKS) tailoring enzymes involved in the production of mithramycin is an effective way of gaining further information regarding the late steps of its biosynthetic pathway. In addition, new "unnatural" natural products of the aureolic acid-type class are likely to be produced. The role of two such post-PKS tailoring enzymes, encoded by mtmC and mtmTIII, was investigated, and four novel aureolic acid class drugs, two premithramycin-type molecules and two mithramycin derivatives, were isolated from mutant strains constructed by insertional gene inactivation of either of these two genes. From data bank comparisons, the corresponding proteins MtmC and MtmTIII were believed to act as a C-methyltransferase involved in the production of the D-mycarose (sugar E) of mithramycin and as a ketoreductase seemingly involved in the biosynthesis of the mithramycin aglycon, respectively. However, gene inactivation and analysis of the accumulated products revealed that both genes encode enzymes participating in the biosynthesis of the D-mycarose building block. Furthermore, the inactivation of MtmC seems to affect the ketoreductase responsible for 4-ketoreduction of sugar C, a D-olivose. Instead of obtaining premithramycin and mithramycin derivatives with a modified E-sugar upon inactivation of mtmC, compounds were obtained that completely lack the E-sugar moiety and that possess an unexpected 4-ketosugar moiety instead of the D-olivose at the beginning of the lower deoxysaccharide chain. The inactivation of mtmTIII led to the accumulation of 4E-ketomithramycin, showing that this ketoreductase is responsible for the 4-ketoreduction of the D-mycarose moiety. The new compounds of the mutant strains, 4A-ketopremithramycin A2, 4A-keto-9-demethylpremithramycin A2, 4C-keto-demycarosylmithramycin, and 4E-ketomithramycin, indicate surprising substrate flexibility of post-PKS enzymes of the mithramycin biosynthetic pathway. Although the glycosyltransferase responsible for the attachment of D-mycarose cannot transfer the unmethylated sugar to the existing lower disaccharide chain, it can transfer the 4-ketoform of sugar E. In addition, the glycosyltransferase MtmGIV, which is responsible for the linkage of sugar C, is also able to transfer an activated 4-ketosugar. The oxygenase MtmOIV, normally responsible for the oxidative cleavage of the tetracyclic premithramycin B into the tricyclic immediate precursor of mithramycin, can act on a substrate analogue with a modified or even incomplete trisaccharide chain. The same is true for glycosyltransferases MtmGI and MtmGII, both of which partake in the formation and attachment of the A-B disaccharide in mithramycin.
光神霉素是由产色链霉菌产生的一种金霉素类抗菌和抗肿瘤药物。修饰参与光神霉素生产的聚酮合酶(PKS)后修饰酶是获取其生物合成途径后期步骤更多信息的有效方法。此外,可能会产生新型的金霉素类“非天然”天然产物。对由mtmC和mtmTIII编码的两种此类PKS后修饰酶的作用进行了研究,并从通过插入失活这两个基因之一构建的突变菌株中分离出了四种新型金霉素类药物、两种前光神霉素型分子和两种光神霉素衍生物。通过数据库比较,相应的蛋白质MtmC和MtmTIII被认为分别作为参与光神霉素D - 麦芽糖(糖E)生产的C - 甲基转移酶和似乎参与光神霉素苷元生物合成的酮还原酶。然而,基因失活和对积累产物的分析表明,这两个基因都编码参与D - 麦芽糖构建块生物合成的酶。此外,MtmC的失活似乎影响负责糖C(一种D - 橄榄糖)4 - 酮还原的酮还原酶。在mtmC失活时,没有获得具有修饰的E - 糖的前光神霉素和光神霉素衍生物,而是获得了完全缺乏E - 糖部分且在下脱氧糖链起始处具有意外的4 - 酮糖部分而非D - 橄榄糖的化合物。mtmTIII的失活导致4E - 酮光神霉素的积累,表明这种酮还原酶负责D - 麦芽糖部分的4 - 酮还原。突变菌株的新化合物4A - 酮前光神霉素A2、4A - 酮 - 9 - 去甲基前光神霉素A2、4C - 酮 - 去麦芽糖基光神霉素和4E - 酮光神霉素表明光神霉素生物合成途径的PKS后修饰酶具有惊人的底物灵活性。尽管负责连接D - 麦芽糖的糖基转移酶不能将未甲基化的糖转移到现有的下二糖链上,但它可以转移糖E的4 - 酮形式。此外,负责连接糖C的糖基转移酶MtmGIV也能够转移活化的4 - 酮糖。通常负责将四环前光神霉素B氧化裂解为光神霉素的三环直接前体的加氧酶MtmOIV,可以作用于具有修饰甚至不完整三糖链的底物类似物。糖基转移酶MtmGI和MtmGII也是如此,它们都参与光神霉素中A - B二糖的形成和连接。